NeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding Minimum Bid Price and Market Value Requirements
April 3, 2026
Diffusion Pharmaceuticals Announces New Date for Previously Announced Special Meeting of Stockholders
April 8, 2022
Related Post
-
-
MiNK Therapeutics and Memorial Sloan Kettering to Present Phase II Study of agenT-797 Combination in PD-1 Refractory Gastroesophageal Cancer at AACR 2026
April 3, 2026
-
BioCardia Files Request for Meeting With FDA to Discuss Accelerated Approval Pathway for CardiAMP® System in Ischemic Heart Failure
April 2, 2026
-
INOVIO Announces Pricing of $17.5 Million Public Offering
April 2, 2026